Diabetes complications

Effect of spironolactone wash‐out on albuminuria after long‐term treatment in individuals with type 2 diabetes and high risk of kidney disease—An observational follow‐up of the PRIORITY study

Diabetes Obes MetabPublished Observational follow-up study of the PRIORITY randomised trial

Authors' conclusion

UACR did not change after discontinuation of long-term treatment with spironolactone. However, an increase in eGFR was observed supporting a haemodynamic effect of spironolactone in the kidneys.

Study context

Population
Individuals with T2D and normoalbuminuria but high risk for progression based on urinary proteomics, re-examined ≈6 weeks after the final PRIORITY visit
Participants
115 individuals
Comparison
Discontinuation of spironolactone vs placebo
  • Spironolactonen = 50
  • Placebon = 65reference
Primary endpoint
Relative change in geometric mean of UACR between the final visit in PRIORITY (baseline) and follow-up
Follow-up
≈6 weeks after the final visit
Methodological detailswash-out after nested randomised part
  • Wash-out after nested randomised part

Primary result

Relative change in geometric mean UACR · follow-up

Relative difference in geometric mean

11%

95% CI −26 to 67

P = 0.60

Change by group

Spironolactone

17%

geometric mean change · 95% CI −12–55

Placebo

5%

geometric mean change · 95% CI −13–26

Between Spironolactone and Placebo
relative difference in geometric mean 11% (95% CI −26 to 67); P = 0.60

As reported in the abstract

Secondary outcomes

Estimated glomerular filtration rate (eGFR), systolic blood pressure (SBP) and serum potassium · follow-up

eGFR and SBP increased after discontinuation of spironolactone
all p < 0.05
SBP increased after placebo discontinuation
all p < 0.05
Potassium lower after discontinuation of spironolactone, higher after placebo discontinuation
all p < 0.05

Original publication

Effect of spironolactone wash‐out on albuminuria after long‐term treatment in individuals with type 2 diabetes and high risk of kidney disease—An observational follow‐up of the PRIORITY study. Diabetes Obes Metab. Published 28 October 2024. doi:10.1111/dom.16037

Composed by AI from the published abstract and checked against it. How Briefs are made →

Get them every week

New studies on this topic in My Week and in your Monday e-mail.

We e-mail you a sign-in link and a code. No password, no spam.